Update on the Management of Aspirin-Exacerbated Respiratory Disease.
Kathleen M BuchheitTanya M LaidlawPublished in: Allergy, asthma & immunology research (2016)
Aspirin-exacerbated respiratory disease (AERD) is an adult-onset upper and lower airway disease consisting of eosinophilic nasal polyps, asthma, and respiratory reactions to cyclooxygenase 1 (COX-1) inhibitors. Management includes guideline-based treatment of asthma and sinus disease, avoidance of COX-1 inhibitors, and for some patients aspirin desensitization followed by high-dose aspirin therapy. Despite this, many patients have inadequately controlled symptoms and require multiple sinus surgeries. In this review, we discuss the current standard approaches to the management of AERD, and we introduce several therapeutics under development that may hold promise for the treatment of AERD.
Keyphrases
- low dose
- end stage renal disease
- high dose
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cardiovascular events
- chronic obstructive pulmonary disease
- antiplatelet therapy
- peritoneal dialysis
- small molecule
- type diabetes
- cardiovascular disease
- chronic rhinosinusitis
- patient reported outcomes
- stem cells
- depressive symptoms
- physical activity
- machine learning
- stem cell transplantation
- cystic fibrosis
- nitric oxide synthase
- allergic rhinitis